Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

745
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
745
Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K
Brain Imaging01:14

Brain Imaging

902
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
902
Amyloid Fibrils03:03

Amyloid Fibrils

12.9K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume.

GeroScience·2026
Same author

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

EBioMedicine·2026
Same author

CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.

medRxiv : the preprint server for health sciences·2026
Same author

Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Complex interplay of astrogliosis and pathology in preclinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Genetic variation in the glymphatic pathway predicts cognition and neurodegeneration in preclinical Alzheimer's disease.

Research square·2026
Same journal

Lactylation in the Ageing Nervous System: Epi-metabolic Regulation, Disease Mechanisms, and Translational Challenges.

Ageing research reviews·2026
Same journal

AI-Driven Advances in Vascular Aging Research: From Mechanisms to Precision Medicine.

Ageing research reviews·2026
Same journal

Brain Health Across the Lifespan and the Impact of Nutrition, Exercise, Microbiota, and Sleep.

Ageing research reviews·2026
Same journal

Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

Ageing research reviews·2026
Same journal

Restoring the balance: Resistance exercise-induced insulin-like growth factor-1 restores PI3K/Akt and MAPK/ERK cross-talk to ameliorate Alzheimer's disease.

Ageing research reviews·2026
Same journal

From organ age gaps to precision geromedicine: multi-omic and imaging frameworks for heterogeneous biological aging.

Ageing research reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.2K

Amyloid imaging: Past, present and future perspectives.

Victor L Villemagne1

  • 1Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia; The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; Department of Medicine, The University of Melbourne, Victoria, Australia.

Ageing Research Reviews
|February 2, 2016
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) diagnosis and prognosis are improved using advanced neuroimaging like PET scans and cerebrospinal fluid (CSF) biomarkers. These methods help track amyloid-beta (Aβ) in clinical trials for new AD therapies.

Keywords:
Alzheimer’s diseaseAβBrain imagingNeurodegenerative disordersPositron emission tomography

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.2K

Related Experiment Videos

Last Updated: Mar 26, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.2K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.2K

Area of Science:

  • Neuroscience
  • Neurology
  • Medical Imaging

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing dementia.
  • Key pathological hallmarks include amyloid-beta (Aβ) plaques and tau neurofibrillary tangles.
  • Synaptic loss and reactive gliosis also characterize AD's progression.

Purpose of the Study:

  • To highlight the diagnostic and prognostic value of neuroimaging and biomarkers in AD.
  • To emphasize the role of these techniques in evaluating novel therapeutic strategies targeting Aβ.

Main Methods:

  • Utilizing functional and molecular neuroimaging, specifically positron emission tomography (PET) with advanced tracers.
  • Analyzing Aβ and tau biomarkers in cerebrospinal fluid (CSF).

Main Results:

  • PET imaging and CSF biomarkers are valuable for differential diagnosis of AD.
  • These techniques aid in establishing disease prognosis.
  • In vivo Aβ burden determination is crucial for therapeutic development.

Conclusions:

  • Neuroimaging and CSF biomarkers are essential tools in managing Alzheimer's disease.
  • These methods are increasingly applied in clinical trials for Aβ-targeting therapies.
  • They facilitate patient selection, assessment of target engagement, and efficacy evaluation.